Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one funded brand of lamotrigine (Logem).
This was the subject of a consultation letter dated 29 August 2018, with a closing date for feedback of 26 September 2018.
After reviewing the feedback, PHARMAC has determined that it requires additional time to consider the issues raised before a decision can be made on the proposal.
This means that a decision will not be made in time to implement the proposal from 1 December 2018, as proposed in the consultation. At this stage PHARMAC does not have a firm timeframe for when a decision will be made.
